Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  BOTULINUM TOXIN
A Global Strategic Business Report

This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The Study Analyzes the Market for ‘Botulinum Toxin’ by the Following Segments: Cosmetic, and Therapeutic (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity). The report provides separate comprehensive analytics for the USA, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2000 through 2015. The report profiles 19 companies including many key and niche players worldwide such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1833  PAGES:    177
PRICE:    $3950  DATE:       April 2009
COMPANIES:  19  MARKET DATA TABLES:   68
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  BOTULINUM TOXIN (Complete Report) Pages : 177   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3
Cosmetic Applications.....I-3
Therapeutic Applications.....I-3
  
II. EXECUTIVE SUMMARY48$2250
  1. Industry Overview.....II-117 $1450  
   A Prelude.....II-1
Botulinum Toxin: “The Science, The Hopes & the Risks”.....II-1
1$100
   Future Opportunities Span Beyond The Developed Markets.....II-2
A Peek Into Noteworthy Trends & Issues.....II-2
Changing Consumer Sentiments.....II-2
1$100
   Aging Population: A Weighty Demographic Driver.....II-3
Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or
  Jubilation?.....II-3
Need for Physician Education Rises With Growing Off Label Usage.....II-3
1$100
   High Voltage Ad Campaigns Boost Patient Awareness.....II-4
Societal Pressure to Look Young Drives up Demand for Facial Aesthetics.....II-4
Cosmetic Botulinum Toxin to Feel the Pinch of the Recession.....II-4
1$100
   Financing of Non-Reimbursed Healthcare: The Need of the Hour.....II-5
Combination Therapies: A Double Whammy Success.....II-5
1$100
   Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments.....II-6
Consolidation Blows in the Aesthetic Healthcare Industry.....II-6
Undesirable Side Effects: A Challenge to Reckon With.....II-6
1$100
   Immunogenicity Undermines Patient Compliance.....II-7
Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo.....II-7
Non-Injectable Alternatives to Turn On the Heat.....II-7
1$100
   Fears of Terrorism & Biological Warfare Thwart International Trade.....II-8
Competition.....II-8
Allergan Wields the Scepter.....II-8
1$100
   Table 1: Revenues of Allergan, Inc (2006 & 2007): Breakdown of Net Sales of Botox/Neuromodulator and Total Revenues (In US$ Million).....II-9

Table 2: European Market for Non-Surgical Cosmetic Procedures (2006): Percentage Share Breakdown of Revenues by Leading Players –Allergan, Q-Med, Mentor Corporation, Mattioli Engineering, Candela, and Others (includes corresponding Graph/Chart).....II-9
1$300
   Table 3: European Market for Non-Surgical Cosmetic Procedures (2009): Percentage Breakdown of Revenues by Type of Procedure –Cosmetic Botulinum Toxin Injections, Facial Fillers, Microdermabrasion, Chemical Peeling, and Aesthetic Lasers (includes corresponding Graph/Chart).....II-10
Reloxin Emerges to Threaten Allergan’s Dominance.....II-10
Reloxin Vs Botox: A Comparison.....II-10
1$300
   Outlook for Allergan’s Botox.....II-111$100
   Market Share Statistics: The New Batting Order.....II-12
Global.....II-12
Table 4: World Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), and Others (includes corresponding Graph/Chart).....II-12

Table 5: World Market for Cosmetic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand –Botox/Vistabel (Allergan) and Dysport/Reloxin (Ipsen/Medicis).....II-12
1$300
   Europe.....II-13
Table 6: European Market for Cosmetic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand –Botox/Vistabel (Allergan) and Dysport (Ipsen).....II-13

Table 7: European Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), and Others (includes corresponding Graph/Chart).....II-13
United States.....II-13
Table 8: US Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/ Brand –Botox (Allergan) and Myobloc (Solstice).....II-13
1$300
   Market Share Statistics: Through the Looking Glass: Year 2012.....II-14
Global.....II-14
Table 9: World Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/ Brand –Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), Puretox (Mentor), Xeomin (Merz), and Others (includes corresponding Graph/Chart).....II-14

Table 10: World Market for Cosmetic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport/Reloxin (Ipsen/Medicis), Xeomin (Merz), and Puretox (Mentor) (includes corresponding Graph/Chart).....II-14
United States.....II-14
Table 11: US Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Myobloc (Solstice), Dysport (Ispen), Puretox (Mentor) and Xeomin (Merz) (includes corresponding Graph/Chart).....II-14
1$300
   Table 12: US Market for Cosmetic Neurotoxins (2008 & 2012P): Percentage Breakdown of Revenues by Company/ Brand –Botox (Allergan), Reloxin (Medicis), and Puretox (Mentor) (includes corresponding Graph/Chart).....II-15
Europe.....II-15
Table 13: European Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), Xeomin (Merz) and Neurobloc (Solstice) (includes corresponding Graph/Chart).....II-15
1$300
   A Peek Into Products Approved & In Pipeline.....II-16
New Treatment Indications for Botulinum Toxin Compounds/Brands in Pipeline As of the
  Year 2008.....II-16
1$100
   List of Botulinum Toxin Products/Brands that are Approved for Various Cosmetic
  Therapeutic Indications As of the Year 2007.....II-17
1$100
  2. Product Overview.....II-1812 $800  
   Botulinum Toxin: A Poison That Cures.....II-18
Structure & Mechanism of Action.....II-18
1$100
   Disadvantages.....II-19
Classification of Botulinum Toxin.....II-19
Botulinum Toxin Type A.....II-19
1$100
   Historical Timeline of Botulinum Toxin: 1885-2002.....II-20
Botox®.....II-20
1$100
   Key Characteristics of Botox® and Botox® Cosmetic.....II-21
Approvals and Indications of Botox in Select Regions.....II-21
1$100
   Common Adverse Reactions with Botox.....II-22
Dysport®/ Reloxin®.....II-22
Key Characteristics of Dysport®.....II-22
1$100
   PurTox®.....II-23
Key Characteristics of PurTox®.....II-23
Xeomin®/ NT-201.....II-23
Key Characteristics of Xeomin®/ NT-201.....II-23
Botulinum Toxin Type B.....II-23
1$100
   Myobloc®/NeuroBloc®.....II-24
Key Characteristics of Myobloc®.....II-24
Applications of Botulinum Toxin.....II-24
Cosmetic Applications.....II-24
1$100
   Glabellar Lines.....II-25
Facial Wrinkles.....II-25
Key Cosmetic Indications for Botulinum Toxin.....II-25
1$100
   Therapeutic Applications.....II-26
Movement Disorders/Pain.....II-26
Cervical Dystonia.....II-26
Hemifacial Spasm.....II-26
Blepharospasm.....II-26
Strabismus.....II-26
1$100
   Chronic Pain.....II-27
Botox in Migraine Treatment.....II-27
1$100
   Hyperhidrosis.....II-28
Bladder Dysfunctions.....II-28
Spasticity.....II-28
Other Applications.....II-28
2$200
  3. Recent Industry Activity.....II-3011 $600  
   Johnson & Johnson Acquires Mentor Corporation.....II-30
Azzalure® Gains Approval from 15 European Countries.....II-30
Inclusion of New Side Effect in Botox and Botox Cosmetic Labels.....II-30
1$100
   Azzalure® Gains Approval for Aesthetic Application in the UK.....II-31
BioForm Medical Acquires Advanced Cosmetic Intervention.....II-31
Galderma to Acquire CollaGenex.....II-31
1$100
   Allergan and Clinique Form Strategic Collaboration.....II-32
Ipsen and Medicis File BLA for Reloxin®.....II-32
Allergan and Clinique Launch New Skin Care Products.....II-32
FDA Accepts Ipsen's Filing for Reloxin.....II-32
GlaxoSmithKline Gains Approval for BOTOX® in Japan.....II-32
Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product.....II-32
1$100
   Allergan Commences Botox Study for Urological Cases in India.....II-33
FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases.....II-33
Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX®.....II-33
Allergan to Set Up a New Subsidiary in India.....II-33
1$100
   Allergan Join Hands with India–Based Kaya.....II-34
Q-Med and Medy-Tox Cancel the Collaboration Agreement.....II-34
Galderma to Increase Awareness in Brazil.....II-34
Allergan to Launch New Products in India.....II-34
Allergan to Establish a State-of-the-Art Botox Training Institute.....II-34
1$100
   Q-Med Inks a Distribution Agreement with Medy -Tox.....II-35
Q-Med Collaborates with Medy-Tox for a Range of Joint Activities.....II-35
Medicis Plans Investment in Revance.....II-35
Galderma Receives Distribution Rights for Dysport (R).....II-35
1$100
   Allergan to Acquire Espirit Pharma.....II-36
Allergan Launches "Project: Sweat Free".....II-36
Solstice Neurosciences Inks Commercialization Agreement.....II-36
Ipsen Partners with Galderma.....II-36
Bio-Med Unveils BOTOGenie.....II-36
Medicis Launches PERLANE.....II-36
1$100
   Studies Underway for Botulinum Toxin Usage for Enlarged Calf Muscles.....II-37
FDA to Assess Reloxin for Cosmetic Use.....II-37
Ipsen Inks Development and Distribution Agreement with Medicis.....II-37
Allergan Rolls Out New Division with Acquisition of Inamed.....II-37
FTC Mandates Allergan Divest Rights to Reloxin.....II-37
1$100
   Medicis Inks Agreement with Ipsen.....II-38
Solstice Neurosciences Inks Licensing Agreement with DreamPharma.....II-38
Botox Enters India Market.....II-38
Mentor Begins Phase-I Clinical Trial on Botulinum Toxin.....II-38
1$100
   Allergan Inks Agreement with GlaxoSmithKline.....II-39
DOR BioPharma Inks Agreement with Dowpharma.....II-39
Merz Pharma Receives Approval for Botulinum Toxin Type A.....II-39
Mentor Initiates Phase-I Clinical Trial.....II-39
Mentor Establishes New Production Facility.....II-39
1$100
   DOR BioPharma and Thomas Jefferson University Teams-Up with US Army.....II-40
Mentor Inks Licensing Agreement with WARF.....II-40
Solstice Acquires World Rights for Myobloc.....II-40
Inamed Rolls Out Reloxin Brand.....II-40
1$100
  4. Focus on Select Key Players.....II-414 $250  
   Allergan, Inc (USA).....II-411$100
   Ipsen Group (France).....II-42
Lanzhou Institute of Biological Products (China).....II-42
1$100
   Metabiologics Inc, (USA).....II-43
Merz Pharmaceuticals GmbH (Germany).....II-43
Mentor Corporation (USA).....II-43
Medy-Tox Incorporated (South Korea).....II-43
1$100
   Medicis Pharmaceutical Corporation (USA).....II-44
Solstice Neurosciences, Inc. (USA).....II-44
1$100
  5. Global Market Perspective.....II-45   
   Table 14: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region/Country – US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-45

Table 15: World 10-Year Perspective for Botulinum Toxin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-45
1$300
   Table 16: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region – US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-46

Table 17: World 10-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-46
1$300
   Table 18: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region – US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-47

Table 19: World 10-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-47
1$300
   Table 20: Global Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-48

Table 21: World 10-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication – Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-48
1$300
III. MARKET30$1950
  1. The United States.....III-118 $1350  
   A. Market Analysis.....III-1
Outlook.....III-1
Cosmetic Procedures: An Overview.....III-1
1$75
   Botox Leads the US Botulinum Toxin Market.....III-2
Botox Approvals and Indications in the US.....III-2
Market Dynamics.....III-2
Booming Non-Surgical Treatments.....III-2
Aging Baby Boomers Drive Aesthetic Business.....III-2
1$75
   Expanding Physician Base Extends Impetus to Growth.....III-3
Demand for Professional Help On the Rise.....III-3
Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin.....III-3
Medical Spas – Growing in Number.....III-3
1$75
   Botulism Poisoning: A Major Concern.....III-4
Botox Injection – Popular Non-Invasive Cosmetic Procedure.....III-4
Table 22: Number of Botox Injections (2000-2005) (includes corresponding Graph/Chart).....III-4

Table 23: Botox Injections by Gender (2004).....III-4
1$150
   Table 24: Botox Injections by Age Group (2004) (includes corresponding Graph/Chart).....III-5
Botox Attracts American Men.....III-5
Table 25: Non-Invasive Cosmetic Procedures in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices (includes corresponding Graph/Chart).....III-5
1$150
   Table 26: Cosmetic Procedures (Surgical/ Non-Surgical) in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices.....III-6
US Cosmetic Market – Statistical Data.....III-6
Table 27: Cosmetic Market in the US (2004 & 2005): Leading Surgical Procedures (includes corresponding Graph/Chart).....III-6
1$150
   Table 28: Cosmetic Market in the US (2004 & 2005): Leading Non-Surgical Procedures (includes corresponding Graph/Chart).....III-7

Table 29: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Gender.....III-7

Table 30: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Age Group (includes corresponding Graph/Chart).....III-7
1$150
   Table 31: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Facility (includes corresponding Graph/Chart).....III-8

Table 32: Cosmetic Market in the US (2004): Percentage Breakdown by Procedure Type.....III-8
Strategic Corporate Developments.....III-8
6$650
   Key Players.....III-143$225
   B. Market Analytics.....III-17
Table 33: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....III-17
1$150
   Table 34: US 10-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-18
1$150
  2. Europe.....III-194 $325  
   A. Market Analysis.....III-19
Outlook.....III-19
European Market - A Primer.....III-19
Botox Approvals and Indications in Select European Countries.....III-19
Botox to Support Radiation Treatments.....III-19
1$75
   Strategic Corporate Developments.....III-20
Key Players.....III-20
1$75
   B. Market Analytics.....III-21
Table 35: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....III-21
1$150
   Table 36: European 10-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-22
1$150
  3. Rest of World.....III-238 $650  
   A. Market Analysis.....III-23
Outlook.....III-23
Asia.....III-23
India – An Emerging Market for Botox.....III-23
South Korea.....III-23
Table 37: Leading Players in the Korean Botulinum Toxin Market (2008): Percentage Breakdown of Sales for Medy-Tox, Allergan, Ipsen, and Lanzhou Institute (includes corresponding Graph/Chart).....III-23
1$150
   Australia – A Well Supported Market.....III-24
Botox Approvals and Indications in Select Asian Countries.....III-24
Botox Approvals and Indications in Select Latin American Regions.....III-24
1$75
   Botox Approvals and Indications in Other Select Global Regions.....III-25
Strategic Corporate Developments.....III-25
3$225
   Key Players .....III-281$75
   B. Market Analytics.....III-29
Table 38: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
   Table 39: Rest of World 10-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-301$150
IV. COMPETITIVE LANDSCAPE 89$995
  
Total Companies Profiled: 399 (including Divisions/Subsidiaries - 408)

Region/Country                 Players


The United States                136   
Canada                            13 
Japan                             14 
Europe                           160  
     France                       10 
     Germany                      38 
     The United Kingdom           47 
     Italy                        20
     Spain                         4
     Rest of Europe               41 
Asia-Pacific (Excluding Japan)    82 
Middle-East                        3
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.